{"transactions":[{"id":2235953,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":126307,"kind":"person","name":"Bolzon Bradley J PhD","position":1,"cik":"0001354345","reported_name":"Bolzon Bradley J PhD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-10T21:35:09.000Z","date":"2022-06-09","kind":"grant","acquired":true,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 9, 2022 with respect to 12,000 Common Shares with 100% of the shares vesting in 12 equal monthly installments beginning on June 30, 2022; provided that the last installment will vest on the earlier of (i) the one year anniversary of the date of grant or (ii) the date of the 2023 Annual General Meeting of Shareholders."}],"balance_after":12000,"derivative":{"exercise_price":71.7,"expiration_date":"2032-06-09","underlying":"Common Shares","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0001209191-22-036031","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000120919122036031/doc4.xml","form_type":"4"}},{"id":2628207,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":126307,"kind":"person","name":"Bolzon Bradley J PhD","position":1,"cik":"0001354345","reported_name":"Bolzon Bradley J PhD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2021-07-21T21:21:33.000Z","date":"2021-07-19","kind":"sale","acquired":false,"shares":700,"price":128.7057,"value":90093.99,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale of these shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."},{"field":"shares","element":"transactionShares","label":"F2","text":"These Securities are held of record by Versant Venture Management, LLC (\"VVM LLC\"), for the benefit of the Reporting Person, pursuant to an agreement between VVM LLC and the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $128.18 to $129.05, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (7) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These securities are held of record by VVM LLC, a portion of which are held for the benefit of the Reporting Person, pursuant to an agreement between VVM LLC and the Reporting Person. The Reporting Person is a managing member of VVM LLC and the Reporting Person may be deemed to indirectly beneficially own the securities through his interest in VVM LLC. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any."}],"balance_after":148831,"source":{"system":"sec-edgar","filing":"0000899243-21-029271","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000089924321029271/doc4.xml","form_type":"4"}},{"id":2628206,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":126307,"kind":"person","name":"Bolzon Bradley J PhD","position":1,"cik":"0001354345","reported_name":"Bolzon Bradley J PhD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2021-07-21T21:21:33.000Z","date":"2021-07-19","kind":"sale","acquired":false,"shares":1324,"price":127.356,"value":168619.344,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale of these shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."},{"field":"shares","element":"transactionShares","label":"F2","text":"These Securities are held of record by Versant Venture Management, LLC (\"VVM LLC\"), for the benefit of the Reporting Person, pursuant to an agreement between VVM LLC and the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $127.02 to $127.85, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (6) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These securities are held of record by VVM LLC, a portion of which are held for the benefit of the Reporting Person, pursuant to an agreement between VVM LLC and the Reporting Person. The Reporting Person is a managing member of VVM LLC and the Reporting Person may be deemed to indirectly beneficially own the securities through his interest in VVM LLC. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any."}],"balance_after":149531,"source":{"system":"sec-edgar","filing":"0000899243-21-029271","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000089924321029271/doc4.xml","form_type":"4"}},{"id":2628205,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":126307,"kind":"person","name":"Bolzon Bradley J PhD","position":1,"cik":"0001354345","reported_name":"Bolzon Bradley J PhD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2021-07-21T21:21:33.000Z","date":"2021-07-19","kind":"sale","acquired":false,"shares":4472,"price":126.4063,"value":565288.9736,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale of these shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."},{"field":"shares","element":"transactionShares","label":"F2","text":"These Securities are held of record by Versant Venture Management, LLC (\"VVM LLC\"), for the benefit of the Reporting Person, pursuant to an agreement between VVM LLC and the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $126.00 to $126.93, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (5) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These securities are held of record by VVM LLC, a portion of which are held for the benefit of the Reporting Person, pursuant to an agreement between VVM LLC and the Reporting Person. The Reporting Person is a managing member of VVM LLC and the Reporting Person may be deemed to indirectly beneficially own the securities through his interest in VVM LLC. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any."}],"balance_after":150855,"source":{"system":"sec-edgar","filing":"0000899243-21-029271","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000089924321029271/doc4.xml","form_type":"4"}},{"id":2628204,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":126307,"kind":"person","name":"Bolzon Bradley J PhD","position":1,"cik":"0001354345","reported_name":"Bolzon Bradley J PhD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2021-07-21T21:21:33.000Z","date":"2021-07-19","kind":"sale","acquired":false,"shares":3504,"price":125.6693,"value":440345.2272,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale of these shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."},{"field":"shares","element":"transactionShares","label":"F2","text":"These Securities are held of record by Versant Venture Management, LLC (\"VVM LLC\"), for the benefit of the Reporting Person, pursuant to an agreement between VVM LLC and the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $125.00 to $125.98, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (3) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These securities are held of record by VVM LLC, a portion of which are held for the benefit of the Reporting Person, pursuant to an agreement between VVM LLC and the Reporting Person. The Reporting Person is a managing member of VVM LLC and the Reporting Person may be deemed to indirectly beneficially own the securities through his interest in VVM LLC. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any."}],"balance_after":155327,"source":{"system":"sec-edgar","filing":"0000899243-21-029271","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000089924321029271/doc4.xml","form_type":"4"}},{"id":2650111,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":126307,"kind":"person","name":"Bolzon Bradley J PhD","position":1,"cik":"0001354345","reported_name":"Bolzon Bradley J PhD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2021-06-30T22:41:42.000Z","date":"2021-06-29","kind":"sale","acquired":false,"shares":1200,"price":152.4217,"value":182906.04,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F27","text":"The sale of these shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F35","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $152.03 to $152.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (35) to this Form 4."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-21-026801","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":25,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000089924321026801/doc4.xml","form_type":"4"}},{"id":2650110,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":126307,"kind":"person","name":"Bolzon Bradley J PhD","position":1,"cik":"0001354345","reported_name":"Bolzon Bradley J PhD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2021-06-30T22:41:42.000Z","date":"2021-06-29","kind":"sale","acquired":false,"shares":6646,"price":151.2431,"value":1005161.6426,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F27","text":"The sale of these shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F34","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $151.00 to $151.98, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (34) to this Form 4."}],"balance_after":1200,"source":{"system":"sec-edgar","filing":"0000899243-21-026801","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":24,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000089924321026801/doc4.xml","form_type":"4"}},{"id":2650109,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":126307,"kind":"person","name":"Bolzon Bradley J PhD","position":1,"cik":"0001354345","reported_name":"Bolzon Bradley J PhD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2021-06-30T22:41:42.000Z","date":"2021-06-29","kind":"sale","acquired":false,"shares":12753,"price":150.493,"value":1919237.229,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F27","text":"The sale of these shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F33","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $150.00 to $150.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (33) to this Form 4."}],"balance_after":7846,"source":{"system":"sec-edgar","filing":"0000899243-21-026801","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":23,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000089924321026801/doc4.xml","form_type":"4"}},{"id":2650108,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":126307,"kind":"person","name":"Bolzon Bradley J PhD","position":1,"cik":"0001354345","reported_name":"Bolzon Bradley J PhD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2021-06-30T22:41:42.000Z","date":"2021-06-29","kind":"sale","acquired":false,"shares":7981,"price":149.4694,"value":1192915.2814,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F27","text":"The sale of these shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F32","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $149.00 to $149.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (32) to this Form 4."}],"balance_after":20599,"source":{"system":"sec-edgar","filing":"0000899243-21-026801","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":22,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000089924321026801/doc4.xml","form_type":"4"}},{"id":2650107,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":126307,"kind":"person","name":"Bolzon Bradley J PhD","position":1,"cik":"0001354345","reported_name":"Bolzon Bradley J PhD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2021-06-30T22:41:42.000Z","date":"2021-06-29","kind":"sale","acquired":false,"shares":12176,"price":148.5788,"value":1809095.4688,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F27","text":"The sale of these shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F31","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $148.00 to $148.97, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (31) to this Form 4."}],"balance_after":28580,"source":{"system":"sec-edgar","filing":"0000899243-21-026801","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":21,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000089924321026801/doc4.xml","form_type":"4"}},{"id":2650106,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":126307,"kind":"person","name":"Bolzon Bradley J PhD","position":1,"cik":"0001354345","reported_name":"Bolzon Bradley J PhD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2021-06-30T22:41:42.000Z","date":"2021-06-29","kind":"sale","acquired":false,"shares":4780,"price":147.4321,"value":704725.438,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F27","text":"The sale of these shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F30","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $147.01 to $147.98, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (30) to this Form 4."}],"balance_after":40756,"source":{"system":"sec-edgar","filing":"0000899243-21-026801","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":20,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000089924321026801/doc4.xml","form_type":"4"}},{"id":2650105,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":126307,"kind":"person","name":"Bolzon Bradley J PhD","position":1,"cik":"0001354345","reported_name":"Bolzon Bradley J PhD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2021-06-30T22:41:42.000Z","date":"2021-06-29","kind":"sale","acquired":false,"shares":600,"price":146.6933,"value":88015.98,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F27","text":"The sale of these shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F29","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $146.00 to $146.90, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (29) to this Form 4."}],"balance_after":45536,"source":{"system":"sec-edgar","filing":"0000899243-21-026801","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":19,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000089924321026801/doc4.xml","form_type":"4"}},{"id":2650104,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":126307,"kind":"person","name":"Bolzon Bradley J PhD","position":1,"cik":"0001354345","reported_name":"Bolzon Bradley J PhD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2021-06-30T22:41:42.000Z","date":"2021-06-29","kind":"sale","acquired":false,"shares":1400,"price":145.9171,"value":204283.94,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F27","text":"The sale of these shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F28","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $145.89 to $145.93, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (28) to this Form 4."}],"balance_after":46136,"source":{"system":"sec-edgar","filing":"0000899243-21-026801","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000089924321026801/doc4.xml","form_type":"4"}},{"id":2650103,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":126307,"kind":"person","name":"Bolzon Bradley J PhD","position":1,"cik":"0001354345","reported_name":"Bolzon Bradley J PhD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2021-06-30T22:41:42.000Z","date":"2021-06-28","kind":"other","acquired":true,"shares":847,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F26","text":"Represents a change in the form of ownership of the Reporting Person by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VV V CAN."}],"balance_after":47536,"source":{"system":"sec-edgar","filing":"0000899243-21-026801","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000089924321026801/doc4.xml","form_type":"4"}},{"id":2650102,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":126307,"kind":"person","name":"Bolzon Bradley J PhD","position":1,"cik":"0001354345","reported_name":"Bolzon Bradley J PhD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2021-06-30T22:41:42.000Z","date":"2021-06-28","kind":"other","acquired":false,"shares":6018,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F25","text":"Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by VV V CAN to its partners."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F24","text":"Shares held by VV V CAN. VV V CAN GP is the sole general partner of VV V CAN. VV V CAN GP may be deemed to have voting and dispositive power over the securities held by VV V CAN and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a director of VV V CAN GP and may be deemed to indirectly beneficially own the securities through his interest in VV V CAN GP. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-21-026801","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000089924321026801/doc4.xml","form_type":"4"}},{"id":2650101,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":126307,"kind":"person","name":"Bolzon Bradley J PhD","position":1,"cik":"0001354345","reported_name":"Bolzon Bradley J PhD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2021-06-30T22:41:42.000Z","date":"2021-06-28","kind":"other","acquired":true,"shares":6018,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F23","text":"Represents a change in the form of ownership of VV V CAN by virtue of the receipt of shares in the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VVC CAN."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F24","text":"Shares held by VV V CAN. VV V CAN GP is the sole general partner of VV V CAN. VV V CAN GP may be deemed to have voting and dispositive power over the securities held by VV V CAN and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a director of VV V CAN GP and may be deemed to indirectly beneficially own the securities through his interest in VV V CAN GP. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any."}],"balance_after":6018,"source":{"system":"sec-edgar","filing":"0000899243-21-026801","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000089924321026801/doc4.xml","form_type":"4"}},{"id":2650100,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":126307,"kind":"person","name":"Bolzon Bradley J PhD","position":1,"cik":"0001354345","reported_name":"Bolzon Bradley J PhD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2021-06-30T22:41:42.000Z","date":"2021-06-28","kind":"other","acquired":false,"shares":27861,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F21","text":"Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Venture Capital V (Canada) LP (\"VVC CAN\") to its partners pursuant to a Rule 10b5-1 trading plan."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F22","text":"These securities are held of record by VVC CAN. Versant Ventures V GP-GP (Canada), Inc. (\"VV V CAN GP\") is the sole general partner of Versant Ventures V (Canada), L.P. (\"VV V CAN\") and VV V CAN is the sole general partner of VVC CAN. Each of VV V CAN GP and VV V CAN may be deemed to have voting and dispositive power over the securities held by VVC CAN and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a director of VV V CAN GP and may be deemed to indirectly beneficially own the securities through his interest in VV V CAN GP. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any."}],"balance_after":16434,"source":{"system":"sec-edgar","filing":"0000899243-21-026801","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000089924321026801/doc4.xml","form_type":"4"}},{"id":2650099,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":126307,"kind":"person","name":"Bolzon Bradley J PhD","position":1,"cik":"0001354345","reported_name":"Bolzon Bradley J PhD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2021-06-30T22:41:42.000Z","date":"2021-06-28","kind":"other","acquired":true,"shares":18973,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F20","text":"Represents a change in the form of ownership of the Reporting Person by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VV V."}],"balance_after":46689,"source":{"system":"sec-edgar","filing":"0000899243-21-026801","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000089924321026801/doc4.xml","form_type":"4"}},{"id":2650098,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":126307,"kind":"person","name":"Bolzon Bradley J PhD","position":1,"cik":"0001354345","reported_name":"Bolzon Bradley J PhD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2021-06-30T22:41:42.000Z","date":"2021-06-28","kind":"other","acquired":false,"shares":84085,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F19","text":"Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by VV V to its members."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F12","text":"Shares held of record by VV V. The Reporting Person is a managing director of VV V and may be deemed to indirectly beneficially own the securities through his interest in VV V. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-21-026801","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000089924321026801/doc4.xml","form_type":"4"}},{"id":2650097,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":126307,"kind":"person","name":"Bolzon Bradley J PhD","position":1,"cik":"0001354345","reported_name":"Bolzon Bradley J PhD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2021-06-30T22:41:42.000Z","date":"2021-06-28","kind":"other","acquired":true,"shares":2633,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F18","text":"Represents a change in the form of ownership of VV V by virtue of the receipt of shares in the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VOA."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F12","text":"Shares held of record by VV V. The Reporting Person is a managing director of VV V and may be deemed to indirectly beneficially own the securities through his interest in VV V. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any."}],"balance_after":84085,"source":{"system":"sec-edgar","filing":"0000899243-21-026801","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000089924321026801/doc4.xml","form_type":"4"}},{"id":2650096,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":126307,"kind":"person","name":"Bolzon Bradley J PhD","position":1,"cik":"0001354345","reported_name":"Bolzon Bradley J PhD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2021-06-30T22:41:42.000Z","date":"2021-06-28","kind":"other","acquired":false,"shares":12189,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F16","text":"Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Ophthalmic Affiliates Fund I, L.P. (\"VOA\") to its partners pursuant to a Rule 10b5-1 trading plan."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F17","text":"These securities are held of record by VOA. VV V is the sole general partner of VOA and may be deemed to have voting and dispositive power over the securities held by VOA and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV V and may be deemed to indirectly beneficially own the securities through his interest in VV V. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any."}],"balance_after":6268,"source":{"system":"sec-edgar","filing":"0000899243-21-026801","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000089924321026801/doc4.xml","form_type":"4"}},{"id":2650095,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":126307,"kind":"person","name":"Bolzon Bradley J PhD","position":1,"cik":"0001354345","reported_name":"Bolzon Bradley J PhD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2021-06-30T22:41:42.000Z","date":"2021-06-28","kind":"other","acquired":true,"shares":2378,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F15","text":"Represents a change in the form of ownership of VV V by virtue of the receipt of shares in the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VAF V."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F12","text":"Shares held of record by VV V. The Reporting Person is a managing director of VV V and may be deemed to indirectly beneficially own the securities through his interest in VV V. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any."}],"balance_after":81452,"source":{"system":"sec-edgar","filing":"0000899243-21-026801","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000089924321026801/doc4.xml","form_type":"4"}},{"id":2650094,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":126307,"kind":"person","name":"Bolzon Bradley J PhD","position":1,"cik":"0001354345","reported_name":"Bolzon Bradley J PhD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2021-06-30T22:41:42.000Z","date":"2021-06-28","kind":"other","acquired":false,"shares":11011,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F13","text":"Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Affiliates Fund V, L.P. (\"VAF V\") to its partners pursuant to a Rule 10b5-1 trading plan."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F14","text":"These securities are held of record by VAF V. VV V is the sole general partner of VAF V and may be deemed to have voting and dispositive power over the securities held by VAF V and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV V and may be deemed to indirectly beneficially own the securities through his interest in VV V. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any."}],"balance_after":5614,"source":{"system":"sec-edgar","filing":"0000899243-21-026801","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000089924321026801/doc4.xml","form_type":"4"}},{"id":2650093,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":126307,"kind":"person","name":"Bolzon Bradley J PhD","position":1,"cik":"0001354345","reported_name":"Bolzon Bradley J PhD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2021-06-30T22:41:42.000Z","date":"2021-06-28","kind":"other","acquired":true,"shares":79074,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F11","text":"Represents a change in the form of ownership of VV V by virtue of the receipt of shares in the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VVC V."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F12","text":"Shares held of record by VV V. The Reporting Person is a managing director of VV V and may be deemed to indirectly beneficially own the securities through his interest in VV V. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any."}],"balance_after":79074,"source":{"system":"sec-edgar","filing":"0000899243-21-026801","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000089924321026801/doc4.xml","form_type":"4"}},{"id":2650092,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":126307,"kind":"person","name":"Bolzon Bradley J PhD","position":1,"cik":"0001354345","reported_name":"Bolzon Bradley J PhD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2021-06-30T22:41:42.000Z","date":"2021-06-28","kind":"other","acquired":false,"shares":366084,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F9","text":"Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Venture Capital V, L.P. (\"VVC V\") to its partners pursuant to a Rule 10b5-1 trading plan."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F10","text":"These securities are held of record by VVC V. Versant Ventures V, LLC (\"VV V\") is the sole general partner of VVC V and may be deemed to have voting and dispositive power over the securities held by VVC V and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV V and may be deemed to indirectly beneficially own the securities through his interest in VV V. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any."}],"balance_after":215915,"source":{"system":"sec-edgar","filing":"0000899243-21-026801","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000089924321026801/doc4.xml","form_type":"4"}},{"id":2650091,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":126307,"kind":"person","name":"Bolzon Bradley J PhD","position":1,"cik":"0001354345","reported_name":"Bolzon Bradley J PhD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2021-06-30T22:41:42.000Z","date":"2021-06-28","kind":"other","acquired":false,"shares":3650,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F7","text":"Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Side Fund IV, L.P. (\"VSF IV\") to its partners pursuant to a Rule 10b5-1 trading plan."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"These securities are held of record by VSF IV. VV IV is the sole general partner of VSF IV and may be deemed to have voting and dispositive power over the securities held by VSF IV and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV IV and may be deemed to indirectly beneficially own the securities through his interest in VV IV. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any."}],"balance_after":622,"source":{"system":"sec-edgar","filing":"0000899243-21-026801","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000089924321026801/doc4.xml","form_type":"4"}},{"id":2650090,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":126307,"kind":"person","name":"Bolzon Bradley J PhD","position":1,"cik":"0001354345","reported_name":"Bolzon Bradley J PhD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2021-06-30T22:41:42.000Z","date":"2021-06-28","kind":"other","acquired":true,"shares":27716,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F6","text":"Represents a change in the form of ownership of the Reporting Person by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VV IV."}],"balance_after":27716,"source":{"system":"sec-edgar","filing":"0000899243-21-026801","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000089924321026801/doc4.xml","form_type":"4"}},{"id":2650089,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":126307,"kind":"person","name":"Bolzon Bradley J PhD","position":1,"cik":"0001354345","reported_name":"Bolzon Bradley J PhD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2021-06-30T22:41:42.000Z","date":"2021-06-28","kind":"other","acquired":false,"shares":158522,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by VV IV to its members."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Shares held of record by VV IV. The Reporting Person is a managing director of VV IV and may be deemed to indirectly beneficially own the securities through his interest in VV IV. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-21-026801","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000089924321026801/doc4.xml","form_type":"4"}},{"id":2650088,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":126307,"kind":"person","name":"Bolzon Bradley J PhD","position":1,"cik":"0001354345","reported_name":"Bolzon Bradley J PhD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2021-06-30T22:41:42.000Z","date":"2021-06-28","kind":"other","acquired":true,"shares":158522,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Represents a change in the form of ownership of VV IV by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VVC IV."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Shares held of record by VV IV. The Reporting Person is a managing director of VV IV and may be deemed to indirectly beneficially own the securities through his interest in VV IV. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any."}],"balance_after":158522,"source":{"system":"sec-edgar","filing":"0000899243-21-026801","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000089924321026801/doc4.xml","form_type":"4"}},{"id":2650087,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":126307,"kind":"person","name":"Bolzon Bradley J PhD","position":1,"cik":"0001354345","reported_name":"Bolzon Bradley J PhD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2021-06-30T22:41:42.000Z","date":"2021-06-28","kind":"other","acquired":false,"shares":615607,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Venture Capital IV, L.P. (\"VVC IV\") to its partners pursuant to a Rule 10b5-1 trading plan."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by VVC IV. Versant Ventures IV, LLC (\"VV IV\") is the sole general partner of VVC IV and may be deemed to have voting and dispositive power over the securities held by VVC IV and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV IV and may be deemed to indirectly beneficially own the securities through his interest in VV IV. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any."}],"balance_after":104874,"source":{"system":"sec-edgar","filing":"0000899243-21-026801","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000089924321026801/doc4.xml","form_type":"4"}},{"id":2650086,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":126307,"kind":"person","name":"Bolzon Bradley J PhD","position":1,"cik":"0001354345","reported_name":"Bolzon Bradley J PhD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2021-06-30T22:38:38.000Z","date":"2021-06-28","kind":"sale","acquired":false,"shares":269,"price":156.5414,"value":42109.6366,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale of these shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."},{"field":"shares","element":"transactionShares","label":"F3","text":"These Securities are held of record by Versant Venture Management, LLC (\"VVM LLC\"), for the benefit of the Reporting Person, pursuant to an agreement between VVM LLC and the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $156.26 to $156.65, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (10) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These securities are held of record by VVM LLC, a portion of which are held for the benefit of the Reporting Person, pursuant to an agreement between VVM LLC and the Reporting Person. The Reporting Person is a managing member of VVM LLC and the Reporting Person may be deemed to indirectly beneficially own the securities through his interest in VVM LLC. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any."}],"balance_after":158831,"source":{"system":"sec-edgar","filing":"0000899243-21-026800","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000089924321026800/doc4.xml","form_type":"4"}},{"id":2650085,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":126307,"kind":"person","name":"Bolzon Bradley J PhD","position":1,"cik":"0001354345","reported_name":"Bolzon Bradley J PhD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2021-06-30T22:38:38.000Z","date":"2021-06-28","kind":"sale","acquired":false,"shares":549,"price":156.5414,"value":85941.2286,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale of these shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $156.26 to $156.65, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (10) to this Form 4."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-21-026800","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000089924321026800/doc4.xml","form_type":"4"}},{"id":2650084,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":126307,"kind":"person","name":"Bolzon Bradley J PhD","position":1,"cik":"0001354345","reported_name":"Bolzon Bradley J PhD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2021-06-30T22:38:38.000Z","date":"2021-06-28","kind":"sale","acquired":false,"shares":132,"price":155.2725,"value":20495.97,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale of these shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."},{"field":"shares","element":"transactionShares","label":"F3","text":"These Securities are held of record by Versant Venture Management, LLC (\"VVM LLC\"), for the benefit of the Reporting Person, pursuant to an agreement between VVM LLC and the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $155.23 to $155.34, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (9) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These securities are held of record by VVM LLC, a portion of which are held for the benefit of the Reporting Person, pursuant to an agreement between VVM LLC and the Reporting Person. The Reporting Person is a managing member of VVM LLC and the Reporting Person may be deemed to indirectly beneficially own the securities through his interest in VVM LLC. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any."}],"balance_after":159100,"source":{"system":"sec-edgar","filing":"0000899243-21-026800","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000089924321026800/doc4.xml","form_type":"4"}},{"id":2650083,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":126307,"kind":"person","name":"Bolzon Bradley J PhD","position":1,"cik":"0001354345","reported_name":"Bolzon Bradley J PhD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2021-06-30T22:38:38.000Z","date":"2021-06-28","kind":"sale","acquired":false,"shares":268,"price":155.2725,"value":41613.03,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale of these shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $155.23 to $155.34, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (9) to this Form 4."}],"balance_after":549,"source":{"system":"sec-edgar","filing":"0000899243-21-026800","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000089924321026800/doc4.xml","form_type":"4"}},{"id":2650082,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":126307,"kind":"person","name":"Bolzon Bradley J PhD","position":1,"cik":"0001354345","reported_name":"Bolzon Bradley J PhD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2021-06-30T22:38:38.000Z","date":"2021-06-28","kind":"sale","acquired":false,"shares":1119,"price":154.5656,"value":172958.9064,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale of these shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."},{"field":"shares","element":"transactionShares","label":"F3","text":"These Securities are held of record by Versant Venture Management, LLC (\"VVM LLC\"), for the benefit of the Reporting Person, pursuant to an agreement between VVM LLC and the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $154.00 to $154.95, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (8) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These securities are held of record by VVM LLC, a portion of which are held for the benefit of the Reporting Person, pursuant to an agreement between VVM LLC and the Reporting Person. The Reporting Person is a managing member of VVM LLC and the Reporting Person may be deemed to indirectly beneficially own the securities through his interest in VVM LLC. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any."}],"balance_after":159232,"source":{"system":"sec-edgar","filing":"0000899243-21-026800","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000089924321026800/doc4.xml","form_type":"4"}},{"id":2650081,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":126307,"kind":"person","name":"Bolzon Bradley J PhD","position":1,"cik":"0001354345","reported_name":"Bolzon Bradley J PhD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2021-06-30T22:38:38.000Z","date":"2021-06-28","kind":"sale","acquired":false,"shares":2281,"price":154.5656,"value":352564.1336,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale of these shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $154.00 to $154.95, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (8) to this Form 4."}],"balance_after":817,"source":{"system":"sec-edgar","filing":"0000899243-21-026800","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000089924321026800/doc4.xml","form_type":"4"}},{"id":2650080,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":126307,"kind":"person","name":"Bolzon Bradley J PhD","position":1,"cik":"0001354345","reported_name":"Bolzon Bradley J PhD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2021-06-30T22:38:38.000Z","date":"2021-06-28","kind":"sale","acquired":false,"shares":2218,"price":153.5389,"value":340549.2802,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale of these shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."},{"field":"shares","element":"transactionShares","label":"F3","text":"These Securities are held of record by Versant Venture Management, LLC (\"VVM LLC\"), for the benefit of the Reporting Person, pursuant to an agreement between VVM LLC and the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $153.02 to $153.97, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (7) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These securities are held of record by VVM LLC, a portion of which are held for the benefit of the Reporting Person, pursuant to an agreement between VVM LLC and the Reporting Person. The Reporting Person is a managing member of VVM LLC and the Reporting Person may be deemed to indirectly beneficially own the securities through his interest in VVM LLC. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any."}],"balance_after":160351,"source":{"system":"sec-edgar","filing":"0000899243-21-026800","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000089924321026800/doc4.xml","form_type":"4"}},{"id":2650079,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":126307,"kind":"person","name":"Bolzon Bradley J PhD","position":1,"cik":"0001354345","reported_name":"Bolzon Bradley J PhD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2021-06-30T22:38:38.000Z","date":"2021-06-28","kind":"sale","acquired":false,"shares":4519,"price":153.5389,"value":693842.2891,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale of these shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $153.02 to $153.97, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (7) to this Form 4."}],"balance_after":3098,"source":{"system":"sec-edgar","filing":"0000899243-21-026800","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000089924321026800/doc4.xml","form_type":"4"}},{"id":2650078,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":126307,"kind":"person","name":"Bolzon Bradley J PhD","position":1,"cik":"0001354345","reported_name":"Bolzon Bradley J PhD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2021-06-30T22:38:38.000Z","date":"2021-06-28","kind":"sale","acquired":false,"shares":1540,"price":152.3763,"value":234659.502,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale of these shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."},{"field":"shares","element":"transactionShares","label":"F3","text":"These Securities are held of record by Versant Venture Management, LLC (\"VVM LLC\"), for the benefit of the Reporting Person, pursuant to an agreement between VVM LLC and the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $152.00 to $152.97, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (6) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These securities are held of record by VVM LLC, a portion of which are held for the benefit of the Reporting Person, pursuant to an agreement between VVM LLC and the Reporting Person. The Reporting Person is a managing member of VVM LLC and the Reporting Person may be deemed to indirectly beneficially own the securities through his interest in VVM LLC. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any."}],"balance_after":162569,"source":{"system":"sec-edgar","filing":"0000899243-21-026800","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000089924321026800/doc4.xml","form_type":"4"}},{"id":2650077,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":126307,"kind":"person","name":"Bolzon Bradley J PhD","position":1,"cik":"0001354345","reported_name":"Bolzon Bradley J PhD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2021-06-30T22:38:38.000Z","date":"2021-06-28","kind":"sale","acquired":false,"shares":3139,"price":152.3763,"value":478309.2057,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale of these shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $152.00 to $152.97, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (6) to this Form 4."}],"balance_after":7617,"source":{"system":"sec-edgar","filing":"0000899243-21-026800","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000089924321026800/doc4.xml","form_type":"4"}},{"id":2650076,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":126307,"kind":"person","name":"Bolzon Bradley J PhD","position":1,"cik":"0001354345","reported_name":"Bolzon Bradley J PhD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2021-06-30T22:38:38.000Z","date":"2021-06-28","kind":"sale","acquired":false,"shares":3144,"price":151.4949,"value":476299.9656,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale of these shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."},{"field":"shares","element":"transactionShares","label":"F3","text":"These Securities are held of record by Versant Venture Management, LLC (\"VVM LLC\"), for the benefit of the Reporting Person, pursuant to an agreement between VVM LLC and the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $151.00 to $151.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (5) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These securities are held of record by VVM LLC, a portion of which are held for the benefit of the Reporting Person, pursuant to an agreement between VVM LLC and the Reporting Person. The Reporting Person is a managing member of VVM LLC and the Reporting Person may be deemed to indirectly beneficially own the securities through his interest in VVM LLC. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any."}],"balance_after":164109,"source":{"system":"sec-edgar","filing":"0000899243-21-026800","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000089924321026800/doc4.xml","form_type":"4"}},{"id":2650075,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":126307,"kind":"person","name":"Bolzon Bradley J PhD","position":1,"cik":"0001354345","reported_name":"Bolzon Bradley J PhD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2021-06-30T22:38:38.000Z","date":"2021-06-28","kind":"sale","acquired":false,"shares":6403,"price":151.4949,"value":970021.8447,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale of these shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $151.00 to $151.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (5) to this Form 4."}],"balance_after":10756,"source":{"system":"sec-edgar","filing":"0000899243-21-026800","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000089924321026800/doc4.xml","form_type":"4"}},{"id":2650074,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":126307,"kind":"person","name":"Bolzon Bradley J PhD","position":1,"cik":"0001354345","reported_name":"Bolzon Bradley J PhD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2021-06-30T22:38:38.000Z","date":"2021-06-28","kind":"sale","acquired":false,"shares":1578,"price":150.6503,"value":237726.1734,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale of these shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."},{"field":"shares","element":"transactionShares","label":"F3","text":"These Securities are held of record by Versant Venture Management, LLC (\"VVM LLC\"), for the benefit of the Reporting Person, pursuant to an agreement between VVM LLC and the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $150.00 to $150.98, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (2) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These securities are held of record by VVM LLC, a portion of which are held for the benefit of the Reporting Person, pursuant to an agreement between VVM LLC and the Reporting Person. The Reporting Person is a managing member of VVM LLC and the Reporting Person may be deemed to indirectly beneficially own the securities through his interest in VVM LLC. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any."}],"balance_after":167253,"source":{"system":"sec-edgar","filing":"0000899243-21-026800","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000089924321026800/doc4.xml","form_type":"4"}},{"id":2650073,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":126307,"kind":"person","name":"Bolzon Bradley J PhD","position":1,"cik":"0001354345","reported_name":"Bolzon Bradley J PhD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2021-06-30T22:38:38.000Z","date":"2021-06-28","kind":"sale","acquired":false,"shares":3216,"price":150.6503,"value":484491.3648,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale of these shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $150.00 to $150.98, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (2) to this Form 4."}],"balance_after":17159,"source":{"system":"sec-edgar","filing":"0000899243-21-026800","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000089924321026800/doc4.xml","form_type":"4"}},{"id":2649547,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":126307,"kind":"person","name":"Bolzon Bradley J PhD","position":1,"cik":"0001354345","reported_name":"Bolzon Bradley J PhD","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C convertible preferred stock","published_at":"2021-06-30T17:05:14.000Z","date":"2021-06-28","kind":"exercise","acquired":false,"shares":2699328,"ownership":{"direct":false,"nature":"By Versant Vantage I, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the \"Preferred Stock\") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a 3.5305-for-one basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the \"Preferred Stock\") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a 3.5305-for-one basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the \"Preferred Stock\") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a 3.5305-for-one basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the \"Preferred Stock\") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a 3.5305-for-one basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares held by Versant Vantage I, L.P. (\"Versant Vantage I\"). Versant Vantage I GP, L.P. (\"Versant Vantage I GP\") is the general partner of Versant Vantage I, and Versant Vantage I GP-GP, LLC (\"Versant Vantage I GP-GP\") is the general partner of Versant Vantage I GP. The Reporting Person is a managing member of Versant Vantage I GP-GP, and may be deemed to share voting and dispositive power over the shares held by Versant Vantage I. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":764573},"source":{"system":"sec-edgar","filing":"0000899243-21-026769","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1354345/000089924321026769/doc4.xml","form_type":"4"}},{"id":2649546,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":126307,"kind":"person","name":"Bolzon Bradley J PhD","position":1,"cik":"0001354345","reported_name":"Bolzon Bradley J PhD","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B convertible preferred stock","published_at":"2021-06-30T17:05:14.000Z","date":"2021-06-28","kind":"exercise","acquired":false,"shares":4150000,"ownership":{"direct":false,"nature":"By Versant Vantage I, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the \"Preferred Stock\") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a 3.5305-for-one basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the \"Preferred Stock\") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a 3.5305-for-one basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the \"Preferred Stock\") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a 3.5305-for-one basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the \"Preferred Stock\") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a 3.5305-for-one basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares held by Versant Vantage I, L.P. (\"Versant Vantage I\"). Versant Vantage I GP, L.P. (\"Versant Vantage I GP\") is the general partner of Versant Vantage I, and Versant Vantage I GP-GP, LLC (\"Versant Vantage I GP-GP\") is the general partner of Versant Vantage I GP. The Reporting Person is a managing member of Versant Vantage I GP-GP, and may be deemed to share voting and dispositive power over the shares held by Versant Vantage I. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1175470},"source":{"system":"sec-edgar","filing":"0000899243-21-026769","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1354345/000089924321026769/doc4.xml","form_type":"4"}},{"id":2649545,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":126307,"kind":"person","name":"Bolzon Bradley J PhD","position":1,"cik":"0001354345","reported_name":"Bolzon Bradley J PhD","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B convertible preferred stock","published_at":"2021-06-30T17:05:14.000Z","date":"2021-06-28","kind":"exercise","acquired":false,"shares":3000000,"ownership":{"direct":false,"nature":"By Versant Capital VI, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the \"Preferred Stock\") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a 3.5305-for-one basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the \"Preferred Stock\") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a 3.5305-for-one basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the \"Preferred Stock\") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a 3.5305-for-one basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the \"Preferred Stock\") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a 3.5305-for-one basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares held by Versant Venture Capital VI, L.P. (\"Versant VI\"). Versant Ventures VI GP, L.P. (\"Versant Ventures VI GP\") is the general partner of Versant VI, and Versant Ventures VI GP-GP, LLC (\"Versant Ventures VI GP-GP\") is the general partner of Versant Ventures VI GP.  The Reporting Person is a managing member of Versant Ventures VI GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant VI. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":849738},"source":{"system":"sec-edgar","filing":"0000899243-21-026769","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1354345/000089924321026769/doc4.xml","form_type":"4"}},{"id":2649544,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":126307,"kind":"person","name":"Bolzon Bradley J PhD","position":1,"cik":"0001354345","reported_name":"Bolzon Bradley J PhD","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A convertible preferred stock","published_at":"2021-06-30T17:05:14.000Z","date":"2021-06-28","kind":"exercise","acquired":false,"shares":20004280,"ownership":{"direct":false,"nature":"By Versant Capital VI, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the \"Preferred Stock\") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a 3.5305-for-one basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the \"Preferred Stock\") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a 3.5305-for-one basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the \"Preferred Stock\") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a 3.5305-for-one basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the \"Preferred Stock\") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a 3.5305-for-one basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares held by Versant Venture Capital VI, L.P. (\"Versant VI\"). Versant Ventures VI GP, L.P. (\"Versant Ventures VI GP\") is the general partner of Versant VI, and Versant Ventures VI GP-GP, LLC (\"Versant Ventures VI GP-GP\") is the general partner of Versant Ventures VI GP.  The Reporting Person is a managing member of Versant Ventures VI GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant VI. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":5666131},"source":{"system":"sec-edgar","filing":"0000899243-21-026769","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1354345/000089924321026769/doc4.xml","form_type":"4"}},{"id":2649543,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":126307,"kind":"person","name":"Bolzon Bradley J PhD","position":1,"cik":"0001354345","reported_name":"Bolzon Bradley J PhD","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-06-30T17:05:14.000Z","date":"2021-06-28","kind":"purchase","acquired":true,"shares":157895,"price":19,"value":3000005.0,"ownership":{"direct":false,"nature":"By Versant Vantage I, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares held by Versant Vantage I, L.P. (\"Versant Vantage I\"). Versant Vantage I GP, L.P. (\"Versant Vantage I GP\") is the general partner of Versant Vantage I, and Versant Vantage I GP-GP, LLC (\"Versant Vantage I GP-GP\") is the general partner of Versant Vantage I GP. The Reporting Person is a managing member of Versant Vantage I GP-GP, and may be deemed to share voting and dispositive power over the shares held by Versant Vantage I. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any."}],"balance_after":2097938,"source":{"system":"sec-edgar","filing":"0000899243-21-026769","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1354345/000089924321026769/doc4.xml","form_type":"4"}},{"id":2649542,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":126307,"kind":"person","name":"Bolzon Bradley J PhD","position":1,"cik":"0001354345","reported_name":"Bolzon Bradley J PhD","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-06-30T17:05:14.000Z","date":"2021-06-28","kind":"exercise","acquired":true,"shares":1940043,"ownership":{"direct":false,"nature":"By Versant Vantage I, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the \"Preferred Stock\") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a 3.5305-for-one basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares held by Versant Vantage I, L.P. (\"Versant Vantage I\"). Versant Vantage I GP, L.P. (\"Versant Vantage I GP\") is the general partner of Versant Vantage I, and Versant Vantage I GP-GP, LLC (\"Versant Vantage I GP-GP\") is the general partner of Versant Vantage I GP. The Reporting Person is a managing member of Versant Vantage I GP-GP, and may be deemed to share voting and dispositive power over the shares held by Versant Vantage I. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any."}],"balance_after":1940043,"source":{"system":"sec-edgar","filing":"0000899243-21-026769","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1354345/000089924321026769/doc4.xml","form_type":"4"}},{"id":2649541,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":126307,"kind":"person","name":"Bolzon Bradley J PhD","position":1,"cik":"0001354345","reported_name":"Bolzon Bradley J PhD","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-06-30T17:05:14.000Z","date":"2021-06-28","kind":"exercise","acquired":true,"shares":6515869,"ownership":{"direct":false,"nature":"By Versant Venture Capital VI, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the \"Preferred Stock\") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a 3.5305-for-one basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares held by Versant Venture Capital VI, L.P. (\"Versant VI\"). Versant Ventures VI GP, L.P. (\"Versant Ventures VI GP\") is the general partner of Versant VI, and Versant Ventures VI GP-GP, LLC (\"Versant Ventures VI GP-GP\") is the general partner of Versant Ventures VI GP.  The Reporting Person is a managing member of Versant Ventures VI GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant VI. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any."}],"balance_after":6799115,"source":{"system":"sec-edgar","filing":"0000899243-21-026769","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1354345/000089924321026769/doc4.xml","form_type":"4"}},{"id":2654528,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":126307,"kind":"person","name":"Bolzon Bradley J PhD","position":1,"cik":"0001354345","reported_name":"Bolzon Bradley J PhD","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-25T17:00:33.000Z","date":"2021-06-23","kind":"grant","acquired":true,"shares":47132,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option shall vest in 36 substantially equal monthly installments, with the first installment vesting on June 28, 2021."}],"balance_after":47132,"derivative":{"exercise_price":19,"expiration_date":"2031-06-22","underlying":"Common Stock","underlying_shares":47132},"source":{"system":"sec-edgar","filing":"0000899243-21-025978","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1354345/000089924321025978/doc4.xml","form_type":"4"}},{"id":2654527,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":126307,"kind":"person","name":"Bolzon Bradley J PhD","position":1,"cik":"0001354345","reported_name":"Bolzon Bradley J PhD","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C convertible preferred stock","published_at":"2021-06-25T17:00:33.000Z","date":"2021-03-11","kind":"grant","acquired":true,"shares":2699328,"price":2.9637,"value":7999998.3936,"ownership":{"direct":false,"nature":"By Versant Vantage I, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series B convertible preferred stock and Series C convertible preferred stock (collectively, the \"Preferred Stock\") is convertible into shares of the Issuer's Common Stock on a 3.5305-for-one basis. Upon the closing of the Issuer's initial public offering, all shares of Preferred Stock will convert into the number of shares of Common Stock of the Issuer shown in column 7. The Preferred Stock has no expiration date."},{"field":"kind","element":"transactionCoding","label":"F2","text":"This transaction occurred prior to the Issuer's initial public offering, and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"). The securities covered by such transaction were previously included on the Reporting Person's Form 3."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series B convertible preferred stock and Series C convertible preferred stock (collectively, the \"Preferred Stock\") is convertible into shares of the Issuer's Common Stock on a 3.5305-for-one basis. Upon the closing of the Issuer's initial public offering, all shares of Preferred Stock will convert into the number of shares of Common Stock of the Issuer shown in column 7. The Preferred Stock has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series B convertible preferred stock and Series C convertible preferred stock (collectively, the \"Preferred Stock\") is convertible into shares of the Issuer's Common Stock on a 3.5305-for-one basis. Upon the closing of the Issuer's initial public offering, all shares of Preferred Stock will convert into the number of shares of Common Stock of the Issuer shown in column 7. The Preferred Stock has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Shares held by Versant Vantage I, L.P. (\"Versant Vantage I\"). Versant Vantage I GP, (\"Versant Vantage I GP\") is the general partner of Versant Vantage I, and Versant Vantage I GP-GP, LLC (\"Versant Vantage I GP-GP\") is the general partner of Versant Vantage I GP. The Reporting Person is a managing member of Versant Vantage I GP-GP, and may be deemed to share voting and dispositive power over the shares held by Versant Vantage I. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any."}],"balance_after":2699328,"derivative":{"underlying":"Common Stock","underlying_shares":764573},"source":{"system":"sec-edgar","filing":"0000899243-21-025978","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1354345/000089924321025978/doc4.xml","form_type":"4"}},{"id":2654526,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":126307,"kind":"person","name":"Bolzon Bradley J PhD","position":1,"cik":"0001354345","reported_name":"Bolzon Bradley J PhD","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B convertible preferred stock","published_at":"2021-06-25T17:00:33.000Z","date":"2021-02-24","kind":"grant","acquired":true,"shares":2075000,"price":2,"value":4150000.0,"ownership":{"direct":false,"nature":"By Versant Vantage I, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series B convertible preferred stock and Series C convertible preferred stock (collectively, the \"Preferred Stock\") is convertible into shares of the Issuer's Common Stock on a 3.5305-for-one basis. Upon the closing of the Issuer's initial public offering, all shares of Preferred Stock will convert into the number of shares of Common Stock of the Issuer shown in column 7. The Preferred Stock has no expiration date."},{"field":"kind","element":"transactionCoding","label":"F2","text":"This transaction occurred prior to the Issuer's initial public offering, and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"). The securities covered by such transaction were previously included on the Reporting Person's Form 3."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series B convertible preferred stock and Series C convertible preferred stock (collectively, the \"Preferred Stock\") is convertible into shares of the Issuer's Common Stock on a 3.5305-for-one basis. Upon the closing of the Issuer's initial public offering, all shares of Preferred Stock will convert into the number of shares of Common Stock of the Issuer shown in column 7. The Preferred Stock has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series B convertible preferred stock and Series C convertible preferred stock (collectively, the \"Preferred Stock\") is convertible into shares of the Issuer's Common Stock on a 3.5305-for-one basis. Upon the closing of the Issuer's initial public offering, all shares of Preferred Stock will convert into the number of shares of Common Stock of the Issuer shown in column 7. The Preferred Stock has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Shares held by Versant Vantage I, L.P. (\"Versant Vantage I\"). Versant Vantage I GP, (\"Versant Vantage I GP\") is the general partner of Versant Vantage I, and Versant Vantage I GP-GP, LLC (\"Versant Vantage I GP-GP\") is the general partner of Versant Vantage I GP. The Reporting Person is a managing member of Versant Vantage I GP-GP, and may be deemed to share voting and dispositive power over the shares held by Versant Vantage I. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any."}],"balance_after":4150000,"derivative":{"underlying":"Common Stock","underlying_shares":587735},"source":{"system":"sec-edgar","filing":"0000899243-21-025978","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1354345/000089924321025978/doc4.xml","form_type":"4"}},{"id":2654525,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":126307,"kind":"person","name":"Bolzon Bradley J PhD","position":1,"cik":"0001354345","reported_name":"Bolzon Bradley J PhD","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B convertible preferred stock","published_at":"2021-06-25T17:00:33.000Z","date":"2021-02-24","kind":"grant","acquired":true,"shares":1500000,"price":2,"value":3000000.0,"ownership":{"direct":false,"nature":"By Versant Capital VI, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series B convertible preferred stock and Series C convertible preferred stock (collectively, the \"Preferred Stock\") is convertible into shares of the Issuer's Common Stock on a 3.5305-for-one basis. Upon the closing of the Issuer's initial public offering, all shares of Preferred Stock will convert into the number of shares of Common Stock of the Issuer shown in column 7. The Preferred Stock has no expiration date."},{"field":"kind","element":"transactionCoding","label":"F2","text":"This transaction occurred prior to the Issuer's initial public offering, and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"). The securities covered by such transaction were previously included on the Reporting Person's Form 3."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series B convertible preferred stock and Series C convertible preferred stock (collectively, the \"Preferred Stock\") is convertible into shares of the Issuer's Common Stock on a 3.5305-for-one basis. Upon the closing of the Issuer's initial public offering, all shares of Preferred Stock will convert into the number of shares of Common Stock of the Issuer shown in column 7. The Preferred Stock has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series B convertible preferred stock and Series C convertible preferred stock (collectively, the \"Preferred Stock\") is convertible into shares of the Issuer's Common Stock on a 3.5305-for-one basis. Upon the closing of the Issuer's initial public offering, all shares of Preferred Stock will convert into the number of shares of Common Stock of the Issuer shown in column 7. The Preferred Stock has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares held by Versant Venture Capital VI, L.P. (\"Versant VI\"). Versant Ventures VI GP, L.P. (\"Versant Ventures VI GP\") is the general partner of Versant VI, and Versant Ventures VI GP-GP, LLC (\"Versant Ventures VI GP-GP\") is the general partner of Versant Ventures VI GP.  The Reporting Person is a managing member of Versant Ventures VI GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant VI. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any."}],"balance_after":3000000,"derivative":{"underlying":"Common Stock","underlying_shares":424869},"source":{"system":"sec-edgar","filing":"0000899243-21-025978","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1354345/000089924321025978/doc4.xml","form_type":"4"}},{"id":2658869,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":126307,"kind":"person","name":"Bolzon Bradley J PhD","position":1,"cik":"0001354345","reported_name":"Bolzon Bradley J PhD","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-22T22:12:19.000Z","date":"2021-06-18","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest and become exercisable in full upon the earlier to occur of (i) June 18, 2022 or (ii) the next annual meeting of the Issuer's stockholders."}],"balance_after":15000,"derivative":{"exercise_price":12.55,"expiration_date":"2031-06-17","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001104659-21-084239","document":"tm2120371-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000110465921084239/tm2120371-1_4seq1.xml","form_type":"4"}},{"id":2668321,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":126307,"kind":"person","name":"Bolzon Bradley J PhD","position":1,"cik":"0001354345","reported_name":"Bolzon Bradley J PhD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2021-06-15T20:41:49.000Z","date":"2021-06-11","kind":"sale","acquired":false,"shares":755,"price":129.4472,"value":97732.636,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale of these shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $129.37 to $129.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (6) to this Form 4."}],"balance_after":20375,"source":{"system":"sec-edgar","filing":"0000899243-21-023880","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000089924321023880/doc4.xml","form_type":"4"}},{"id":2668320,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":126307,"kind":"person","name":"Bolzon Bradley J PhD","position":1,"cik":"0001354345","reported_name":"Bolzon Bradley J PhD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2021-06-15T20:41:49.000Z","date":"2021-06-11","kind":"sale","acquired":false,"shares":1100,"price":128.6518,"value":141516.98,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale of these shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $128.29 to $129.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (5) to this Form 4."}],"balance_after":21130,"source":{"system":"sec-edgar","filing":"0000899243-21-023880","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000089924321023880/doc4.xml","form_type":"4"}},{"id":2668319,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":126307,"kind":"person","name":"Bolzon Bradley J PhD","position":1,"cik":"0001354345","reported_name":"Bolzon Bradley J PhD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2021-06-15T20:41:49.000Z","date":"2021-06-11","kind":"sale","acquired":false,"shares":800,"price":127.8838,"value":102307.04,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale of these shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $127.29 to $128.26, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (4) to this Form 4."}],"balance_after":22230,"source":{"system":"sec-edgar","filing":"0000899243-21-023880","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000089924321023880/doc4.xml","form_type":"4"}},{"id":2668318,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":126307,"kind":"person","name":"Bolzon Bradley J PhD","position":1,"cik":"0001354345","reported_name":"Bolzon Bradley J PhD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2021-06-15T20:41:49.000Z","date":"2021-06-11","kind":"sale","acquired":false,"shares":1918,"price":126.5946,"value":242808.4428,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale of these shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $126.14 to $127.09, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (3) to this Form 4."}],"balance_after":23030,"source":{"system":"sec-edgar","filing":"0000899243-21-023880","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000089924321023880/doc4.xml","form_type":"4"}},{"id":2668317,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":126307,"kind":"person","name":"Bolzon Bradley J PhD","position":1,"cik":"0001354345","reported_name":"Bolzon Bradley J PhD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2021-06-15T20:41:49.000Z","date":"2021-06-11","kind":"sale","acquired":false,"shares":5427,"price":125.6225,"value":681753.3075,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale of these shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $125.13 to $126.11, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (2) to this Form 4."}],"balance_after":24948,"source":{"system":"sec-edgar","filing":"0000899243-21-023880","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000089924321023880/doc4.xml","form_type":"4"}},{"id":2670218,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":126307,"kind":"person","name":"Bolzon Bradley J PhD","position":1,"cik":"0001354345","reported_name":"Bolzon Bradley J PhD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-14T21:36:38.000Z","date":"2021-06-10","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 10, 2021 with respect to 10,000 Common Shares with 100% of the shares vesting in 12 equal monthly installments beginning on June 30, 2021; provided that the last installment will vest on the earlier of (i) the one year anniversary of the date of grant or (ii) the date of the 2022 Annual General Meeting of Shareholders."}],"balance_after":10000,"derivative":{"exercise_price":123.71,"expiration_date":"2031-06-10","underlying":"Common Shares","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001209191-21-040292","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000120919121040292/doc4.xml","form_type":"4"}},{"id":2773207,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":126307,"kind":"person","name":"Bolzon Bradley J PhD","position":1,"cik":"0001354345","reported_name":"Bolzon Bradley J PhD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2021-03-24T22:00:11.000Z","date":"2021-03-22","kind":"sale","acquired":false,"shares":300,"price":134.9267,"value":40478.01,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale of these shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $134.88 to $135.01, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (8) to this Form 4."}],"balance_after":30375,"source":{"system":"sec-edgar","filing":"0000899243-21-013316","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000089924321013316/doc4.xml","form_type":"4"}},{"id":2773206,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":126307,"kind":"person","name":"Bolzon Bradley J PhD","position":1,"cik":"0001354345","reported_name":"Bolzon Bradley J PhD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2021-03-24T22:00:11.000Z","date":"2021-03-22","kind":"sale","acquired":false,"shares":5237,"price":134.3317,"value":703495.1129,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale of these shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $133.87 to $134.79, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (7) to this Form 4."}],"balance_after":30675,"source":{"system":"sec-edgar","filing":"0000899243-21-013316","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000089924321013316/doc4.xml","form_type":"4"}},{"id":2773205,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":126307,"kind":"person","name":"Bolzon Bradley J PhD","position":1,"cik":"0001354345","reported_name":"Bolzon Bradley J PhD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2021-03-24T22:00:11.000Z","date":"2021-03-22","kind":"sale","acquired":false,"shares":9334,"price":133.2837,"value":1244070.0558,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale of these shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $132.86 to $133.82, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (6) to this Form 4."}],"balance_after":35912,"source":{"system":"sec-edgar","filing":"0000899243-21-013316","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000089924321013316/doc4.xml","form_type":"4"}},{"id":2773204,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":126307,"kind":"person","name":"Bolzon Bradley J PhD","position":1,"cik":"0001354345","reported_name":"Bolzon Bradley J PhD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2021-03-24T22:00:11.000Z","date":"2021-03-22","kind":"sale","acquired":false,"shares":6090,"price":132.5275,"value":807092.475,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale of these shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $131.86 to $132.84, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (5) to this Form 4."}],"balance_after":45246,"source":{"system":"sec-edgar","filing":"0000899243-21-013316","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000089924321013316/doc4.xml","form_type":"4"}},{"id":2773203,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":126307,"kind":"person","name":"Bolzon Bradley J PhD","position":1,"cik":"0001354345","reported_name":"Bolzon Bradley J PhD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2021-03-24T22:00:11.000Z","date":"2021-03-22","kind":"sale","acquired":false,"shares":2400,"price":131.1422,"value":314741.28,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale of these shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $130.75 to $131.65, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (4) to this Form 4."}],"balance_after":51336,"source":{"system":"sec-edgar","filing":"0000899243-21-013316","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000089924321013316/doc4.xml","form_type":"4"}},{"id":2773202,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":126307,"kind":"person","name":"Bolzon Bradley J PhD","position":1,"cik":"0001354345","reported_name":"Bolzon Bradley J PhD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2021-03-24T22:00:11.000Z","date":"2021-03-22","kind":"sale","acquired":false,"shares":3413,"price":130.4166,"value":445111.8558,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale of these shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $129.75 to $130.74, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (3) to this Form 4."}],"balance_after":53736,"source":{"system":"sec-edgar","filing":"0000899243-21-013316","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000089924321013316/doc4.xml","form_type":"4"}},{"id":2773201,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":126307,"kind":"person","name":"Bolzon Bradley J PhD","position":1,"cik":"0001354345","reported_name":"Bolzon Bradley J PhD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2021-03-24T22:00:11.000Z","date":"2021-03-22","kind":"sale","acquired":false,"shares":3600,"price":129.355,"value":465678.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale of these shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $128.74 to $129.73, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (2) to this Form 4."}],"balance_after":57149,"source":{"system":"sec-edgar","filing":"0000899243-21-013316","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000089924321013316/doc4.xml","form_type":"4"}},{"id":2813762,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":126307,"kind":"person","name":"Bolzon Bradley J PhD","position":1,"cik":"0001354345","reported_name":"Bolzon Bradley J PhD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2021-03-03T21:23:12.000Z","date":"2021-03-01","kind":"other","acquired":true,"shares":565,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F18","text":"Represents a change in the form of ownership of the Reporting Person by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VV V CAN."}],"balance_after":60749,"source":{"system":"sec-edgar","filing":"0000899243-21-009385","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000089924321009385/doc4.xml","form_type":"4"}},{"id":2813761,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":126307,"kind":"person","name":"Bolzon Bradley J PhD","position":1,"cik":"0001354345","reported_name":"Bolzon Bradley J PhD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2021-03-03T21:23:12.000Z","date":"2021-03-01","kind":"other","acquired":false,"shares":4012,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F17","text":"Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by VV V CAN to its partners."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F16","text":"Shares held by VV V CAN. VV V CAN GP is the sole general partner of VV V CAN. VV V CAN GP may be deemed to have voting and dispositive power over the securities held by VV V CAN and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a director of VV V CAN GP and may be deemed to indirectly beneficially own the securities through his interest in VV V CAN GP. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-21-009385","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000089924321009385/doc4.xml","form_type":"4"}},{"id":2813760,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":126307,"kind":"person","name":"Bolzon Bradley J PhD","position":1,"cik":"0001354345","reported_name":"Bolzon Bradley J PhD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2021-03-03T21:23:12.000Z","date":"2021-03-01","kind":"other","acquired":true,"shares":4012,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F15","text":"Represents a change in the form of ownership of VV V CAN by virtue of the receipt of shares in the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VVC CAN."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F16","text":"Shares held by VV V CAN. VV V CAN GP is the sole general partner of VV V CAN. VV V CAN GP may be deemed to have voting and dispositive power over the securities held by VV V CAN and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a director of VV V CAN GP and may be deemed to indirectly beneficially own the securities through his interest in VV V CAN GP. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any."}],"balance_after":4012,"source":{"system":"sec-edgar","filing":"0000899243-21-009385","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000089924321009385/doc4.xml","form_type":"4"}},{"id":2813759,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":126307,"kind":"person","name":"Bolzon Bradley J PhD","position":1,"cik":"0001354345","reported_name":"Bolzon Bradley J PhD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2021-03-03T21:23:12.000Z","date":"2021-03-01","kind":"other","acquired":false,"shares":18574,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F13","text":"Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Venture Capital V (Canada) LP (\"VVC CAN\") to its partners pursuant to a Rule 10b5-1 trading plan."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F14","text":"These securities are held of record by VVC CAN. Versant Ventures V GP-GP (Canada), Inc. (\"VV V CAN GP\") is the sole general partner of Versant Ventures V (Canada), L.P. (\"VV V CAN\") and VV V CAN is the sole general partner of VVC CAN. Each of VV V CAN GP and VV V CAN may be deemed to have voting and dispositive power over the securities held by VVC CAN and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a director of VV V CAN GP and may be deemed to indirectly beneficially own the securities through his interest in VV V CAN GP. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any."}],"balance_after":44295,"source":{"system":"sec-edgar","filing":"0000899243-21-009385","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000089924321009385/doc4.xml","form_type":"4"}},{"id":2813758,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":126307,"kind":"person","name":"Bolzon Bradley J PhD","position":1,"cik":"0001354345","reported_name":"Bolzon Bradley J PhD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2021-03-03T21:23:12.000Z","date":"2021-03-01","kind":"other","acquired":true,"shares":12648,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F12","text":"Represents a change in the form of ownership of the Reporting Person by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VV V."}],"balance_after":60184,"source":{"system":"sec-edgar","filing":"0000899243-21-009385","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000089924321009385/doc4.xml","form_type":"4"}},{"id":2813757,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":126307,"kind":"person","name":"Bolzon Bradley J PhD","position":1,"cik":"0001354345","reported_name":"Bolzon Bradley J PhD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2021-03-03T21:23:12.000Z","date":"2021-03-01","kind":"other","acquired":false,"shares":56056,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F11","text":"Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by VV V to its members."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Shares held of record by VV V. The Reporting Person is a managing director of VV V and may be deemed to indirectly beneficially own the securities through his interest in VV V. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-21-009385","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000089924321009385/doc4.xml","form_type":"4"}},{"id":2813756,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":126307,"kind":"person","name":"Bolzon Bradley J PhD","position":1,"cik":"0001354345","reported_name":"Bolzon Bradley J PhD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2021-03-03T21:23:12.000Z","date":"2021-03-01","kind":"other","acquired":true,"shares":1755,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F10","text":"Represents a change in the form of ownership of VV V by virtue of the receipt of shares in the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VOA."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Shares held of record by VV V. The Reporting Person is a managing director of VV V and may be deemed to indirectly beneficially own the securities through his interest in VV V. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any."}],"balance_after":56056,"source":{"system":"sec-edgar","filing":"0000899243-21-009385","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000089924321009385/doc4.xml","form_type":"4"}},{"id":2813755,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":126307,"kind":"person","name":"Bolzon Bradley J PhD","position":1,"cik":"0001354345","reported_name":"Bolzon Bradley J PhD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2021-03-03T21:23:12.000Z","date":"2021-03-01","kind":"other","acquired":false,"shares":8126,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F8","text":"Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Ophthalmic Affiliates Fund I, L.P. (\"VOA\") to its partners pursuant to a Rule 10b5-1 trading plan."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"These securities are held of record by VOA. VV V is the sole general partner of VOA and may be deemed to have voting and dispositive power over the securities held by VOA and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV V and may be deemed to indirectly beneficially own the securities through his interest in VV V. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any."}],"balance_after":18457,"source":{"system":"sec-edgar","filing":"0000899243-21-009385","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000089924321009385/doc4.xml","form_type":"4"}},{"id":2813754,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":126307,"kind":"person","name":"Bolzon Bradley J PhD","position":1,"cik":"0001354345","reported_name":"Bolzon Bradley J PhD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2021-03-03T21:23:12.000Z","date":"2021-03-01","kind":"other","acquired":true,"shares":1585,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F7","text":"Represents a change in the form of ownership of VV V by virtue of the receipt of shares in the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VAF V."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Shares held of record by VV V. The Reporting Person is a managing director of VV V and may be deemed to indirectly beneficially own the securities through his interest in VV V. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any."}],"balance_after":54301,"source":{"system":"sec-edgar","filing":"0000899243-21-009385","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000089924321009385/doc4.xml","form_type":"4"}},{"id":2813753,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":126307,"kind":"person","name":"Bolzon Bradley J PhD","position":1,"cik":"0001354345","reported_name":"Bolzon Bradley J PhD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2021-03-03T21:23:12.000Z","date":"2021-03-01","kind":"other","acquired":false,"shares":7341,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Affiliates Fund V, L.P. (\"VAF V\") to its partners pursuant to a Rule 10b5-1 trading plan."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"These securities are held of record by VAF V. VV V is the sole general partner of VAF V and may be deemed to have voting and dispositive power over the securities held by VAF V and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV V and may be deemed to indirectly beneficially own the securities through his interest in VV V. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any."}],"balance_after":16625,"source":{"system":"sec-edgar","filing":"0000899243-21-009385","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000089924321009385/doc4.xml","form_type":"4"}},{"id":2813752,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":126307,"kind":"person","name":"Bolzon Bradley J PhD","position":1,"cik":"0001354345","reported_name":"Bolzon Bradley J PhD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2021-03-03T21:23:12.000Z","date":"2021-03-01","kind":"other","acquired":true,"shares":52716,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Represents a change in the form of ownership of VV V by virtue of the receipt of shares in the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VVC V."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Shares held of record by VV V. The Reporting Person is a managing director of VV V and may be deemed to indirectly beneficially own the securities through his interest in VV V. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any."}],"balance_after":52716,"source":{"system":"sec-edgar","filing":"0000899243-21-009385","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000089924321009385/doc4.xml","form_type":"4"}},{"id":2813751,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":126307,"kind":"person","name":"Bolzon Bradley J PhD","position":1,"cik":"0001354345","reported_name":"Bolzon Bradley J PhD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2021-03-03T21:23:12.000Z","date":"2021-03-01","kind":"other","acquired":false,"shares":244056,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Venture Capital V, L.P. (\"VVC V\") to its partners pursuant to a Rule 10b5-1 trading plan."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by VVC V. Versant Ventures V, LLC (\"VV V\") is the sole general partner of VVC V and may be deemed to have voting and dispositive power over the securities held by VVC V and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV V and may be deemed to indirectly beneficially own the securities through his interest in VV V. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any."}],"balance_after":581999,"source":{"system":"sec-edgar","filing":"0000899243-21-009385","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000089924321009385/doc4.xml","form_type":"4"}},{"id":2839512,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":126307,"kind":"person","name":"Bolzon Bradley J PhD","position":1,"cik":"0001354345","reported_name":"Bolzon Bradley J PhD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2021-02-23T21:40:01.000Z","date":"2021-02-19","kind":"other","acquired":true,"shares":847,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F33","text":"Represents a change in the form of ownership of the Reporting Person by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VV V CAN."}],"balance_after":47536,"source":{"system":"sec-edgar","filing":"0000899243-21-007816","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":22,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000089924321007816/doc4.xml","form_type":"4"}},{"id":2839511,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":126307,"kind":"person","name":"Bolzon Bradley J PhD","position":1,"cik":"0001354345","reported_name":"Bolzon Bradley J PhD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2021-02-23T21:40:01.000Z","date":"2021-02-19","kind":"other","acquired":false,"shares":6018,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F32","text":"Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by VV V CAN to its partners."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F31","text":"Shares held by VV V CAN. VV V CAN GP is the sole general partner of VV V CAN. VV V CAN GP may be deemed to have voting and dispositive power over the securities held by VV V CAN and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a director of VV V CAN GP and may be deemed to indirectly beneficially own the securities through his interest in VV V CAN GP. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-21-007816","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":21,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000089924321007816/doc4.xml","form_type":"4"}},{"id":2839510,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":126307,"kind":"person","name":"Bolzon Bradley J PhD","position":1,"cik":"0001354345","reported_name":"Bolzon Bradley J PhD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2021-02-23T21:40:01.000Z","date":"2021-02-19","kind":"other","acquired":true,"shares":6018,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F30","text":"Represents a change in the form of ownership of VV V CAN by virtue of the receipt of shares in the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VVC CAN."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F31","text":"Shares held by VV V CAN. VV V CAN GP is the sole general partner of VV V CAN. VV V CAN GP may be deemed to have voting and dispositive power over the securities held by VV V CAN and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a director of VV V CAN GP and may be deemed to indirectly beneficially own the securities through his interest in VV V CAN GP. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any."}],"balance_after":6018,"source":{"system":"sec-edgar","filing":"0000899243-21-007816","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":20,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000089924321007816/doc4.xml","form_type":"4"}},{"id":2839509,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":126307,"kind":"person","name":"Bolzon Bradley J PhD","position":1,"cik":"0001354345","reported_name":"Bolzon Bradley J PhD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2021-02-23T21:40:01.000Z","date":"2021-02-19","kind":"other","acquired":false,"shares":27861,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F28","text":"Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Venture Capital V (Canada) LP (\"VVC CAN\") to its partners."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F29","text":"These securities are held of record by VVC CAN. Versant Ventures V GP-GP (Canada), Inc. (\"VV V CAN GP\") is the sole general partner of Versant Ventures V (Canada), L.P. (\"VV V CAN\") and VV V CAN is the sole general partner of VVC CAN. Each of VV V CAN GP and VV V CAN may be deemed to have voting and dispositive power over the securities held by VVC CAN and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a director of VV V CAN GP and may be deemed to indirectly beneficially own the securities through his interest in VV V CAN GP. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any."}],"balance_after":62869,"source":{"system":"sec-edgar","filing":"0000899243-21-007816","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":19,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000089924321007816/doc4.xml","form_type":"4"}},{"id":2839508,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":126307,"kind":"person","name":"Bolzon Bradley J PhD","position":1,"cik":"0001354345","reported_name":"Bolzon Bradley J PhD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2021-02-23T21:40:01.000Z","date":"2021-02-19","kind":"other","acquired":true,"shares":18973,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F27","text":"Represents a change in the form of ownership of the Reporting Person by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VV V."}],"balance_after":46689,"source":{"system":"sec-edgar","filing":"0000899243-21-007816","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000089924321007816/doc4.xml","form_type":"4"}},{"id":2839507,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":126307,"kind":"person","name":"Bolzon Bradley J PhD","position":1,"cik":"0001354345","reported_name":"Bolzon Bradley J PhD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2021-02-23T21:40:01.000Z","date":"2021-02-19","kind":"other","acquired":false,"shares":84085,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F26","text":"Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by VV V to its members."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F19","text":"Shares held of record by VV V. The Reporting Person is a managing director of VV V and may be deemed to indirectly beneficially own the securities through his interest in VV V. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-21-007816","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000089924321007816/doc4.xml","form_type":"4"}},{"id":2839506,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":126307,"kind":"person","name":"Bolzon Bradley J PhD","position":1,"cik":"0001354345","reported_name":"Bolzon Bradley J PhD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2021-02-23T21:40:01.000Z","date":"2021-02-19","kind":"other","acquired":true,"shares":2633,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F25","text":"Represents a change in the form of ownership of VV V by virtue of the receipt of shares in the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VOA."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F19","text":"Shares held of record by VV V. The Reporting Person is a managing director of VV V and may be deemed to indirectly beneficially own the securities through his interest in VV V. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any."}],"balance_after":84085,"source":{"system":"sec-edgar","filing":"0000899243-21-007816","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000089924321007816/doc4.xml","form_type":"4"}},{"id":2839505,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":126307,"kind":"person","name":"Bolzon Bradley J PhD","position":1,"cik":"0001354345","reported_name":"Bolzon Bradley J PhD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2021-02-23T21:40:01.000Z","date":"2021-02-19","kind":"other","acquired":false,"shares":12189,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F23","text":"Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Ophthalmic Affiliates Fund I, L.P. (\"VOA\") to its partners."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F24","text":"These securities are held of record by VOA. VV V is the sole general partner of VOA and may be deemed to have voting and dispositive power over the securities held by VOA and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV V and may be deemed to indirectly beneficially own the securities through his interest in VV V. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any."}],"balance_after":26583,"source":{"system":"sec-edgar","filing":"0000899243-21-007816","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000089924321007816/doc4.xml","form_type":"4"}},{"id":2839504,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":126307,"kind":"person","name":"Bolzon Bradley J PhD","position":1,"cik":"0001354345","reported_name":"Bolzon Bradley J PhD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2021-02-23T21:40:01.000Z","date":"2021-02-19","kind":"other","acquired":true,"shares":2378,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F22","text":"Represents a change in the form of ownership of VV V by virtue of the receipt of shares in the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VAF V."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F19","text":"Shares held of record by VV V. The Reporting Person is a managing director of VV V and may be deemed to indirectly beneficially own the securities through his interest in VV V. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any."}],"balance_after":81452,"source":{"system":"sec-edgar","filing":"0000899243-21-007816","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000089924321007816/doc4.xml","form_type":"4"}},{"id":2839503,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":126307,"kind":"person","name":"Bolzon Bradley J PhD","position":1,"cik":"0001354345","reported_name":"Bolzon Bradley J PhD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2021-02-23T21:40:01.000Z","date":"2021-02-19","kind":"other","acquired":false,"shares":11011,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F20","text":"Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Affiliates Fund V, L.P. (\"VAF V\") to its partners."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F21","text":"These securities are held of record by VAF V. VV V is the sole general partner of VAF V and may be deemed to have voting and dispositive power over the securities held by VAF V and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV V and may be deemed to indirectly beneficially own the securities through his interest in VV V. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any."}],"balance_after":23966,"source":{"system":"sec-edgar","filing":"0000899243-21-007816","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000089924321007816/doc4.xml","form_type":"4"}},{"id":2839502,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":126307,"kind":"person","name":"Bolzon Bradley J PhD","position":1,"cik":"0001354345","reported_name":"Bolzon Bradley J PhD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2021-02-23T21:40:01.000Z","date":"2021-02-19","kind":"other","acquired":true,"shares":79074,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F18","text":"Represents a change in the form of ownership of VV V by virtue of the receipt of shares in the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VVC V."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F19","text":"Shares held of record by VV V. The Reporting Person is a managing director of VV V and may be deemed to indirectly beneficially own the securities through his interest in VV V. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any."}],"balance_after":79074,"source":{"system":"sec-edgar","filing":"0000899243-21-007816","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000089924321007816/doc4.xml","form_type":"4"}},{"id":2839501,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":126307,"kind":"person","name":"Bolzon Bradley J PhD","position":1,"cik":"0001354345","reported_name":"Bolzon Bradley J PhD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2021-02-23T21:40:01.000Z","date":"2021-02-19","kind":"other","acquired":false,"shares":366084,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F16","text":"Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Venture Capital V, L.P. (\"VVC V\") to its partners."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F17","text":"These securities are held of record by VVC V. Versant Ventures V, LLC (\"VV V\") is the sole general partner of VVC V and may be deemed to have voting and dispositive power over the securities held by VVC V and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV V and may be deemed to indirectly beneficially own the securities through his interest in VV V. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any."}],"balance_after":826055,"source":{"system":"sec-edgar","filing":"0000899243-21-007816","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000089924321007816/doc4.xml","form_type":"4"}},{"id":2839500,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":126307,"kind":"person","name":"Bolzon Bradley J PhD","position":1,"cik":"0001354345","reported_name":"Bolzon Bradley J PhD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2021-02-23T21:40:01.000Z","date":"2021-02-19","kind":"other","acquired":false,"shares":3650,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F14","text":"Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Side Fund IV, L.P. (\"VSF IV\") to its partners."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F15","text":"These securities are held of record by VSF IV. VV IV is the sole general partner of VSF IV and may be deemed to have voting and dispositive power over the securities held by VSF IV and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV IV and may be deemed to indirectly beneficially own the securities through his interest in VV IV. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any."}],"balance_after":4272,"source":{"system":"sec-edgar","filing":"0000899243-21-007816","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000089924321007816/doc4.xml","form_type":"4"}},{"id":2839499,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":126307,"kind":"person","name":"Bolzon Bradley J PhD","position":1,"cik":"0001354345","reported_name":"Bolzon Bradley J PhD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2021-02-23T21:40:01.000Z","date":"2021-02-19","kind":"other","acquired":true,"shares":27716,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F13","text":"Represents a change in the form of ownership of the Reporting Person by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VV IV."}],"balance_after":27716,"source":{"system":"sec-edgar","filing":"0000899243-21-007816","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000089924321007816/doc4.xml","form_type":"4"}},{"id":2839498,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":126307,"kind":"person","name":"Bolzon Bradley J PhD","position":1,"cik":"0001354345","reported_name":"Bolzon Bradley J PhD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2021-02-23T21:40:01.000Z","date":"2021-02-19","kind":"other","acquired":false,"shares":158522,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F12","text":"Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by VV IV to its members."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F11","text":"Shares held of record by VV IV. The Reporting Person is a managing director of VV IV and may be deemed to indirectly beneficially own the securities through his interest in VV IV. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-21-007816","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000089924321007816/doc4.xml","form_type":"4"}},{"id":2839497,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":126307,"kind":"person","name":"Bolzon Bradley J PhD","position":1,"cik":"0001354345","reported_name":"Bolzon Bradley J PhD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2021-02-23T21:40:01.000Z","date":"2021-02-19","kind":"other","acquired":true,"shares":158522,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F10","text":"Represents a change in the form of ownership of VV IV by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VVC IV."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F11","text":"Shares held of record by VV IV. The Reporting Person is a managing director of VV IV and may be deemed to indirectly beneficially own the securities through his interest in VV IV. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any."}],"balance_after":158522,"source":{"system":"sec-edgar","filing":"0000899243-21-007816","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000089924321007816/doc4.xml","form_type":"4"}},{"id":2839496,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":126307,"kind":"person","name":"Bolzon Bradley J PhD","position":1,"cik":"0001354345","reported_name":"Bolzon Bradley J PhD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2021-02-23T21:40:01.000Z","date":"2021-02-19","kind":"other","acquired":false,"shares":615607,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F8","text":"Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Venture Capital IV, L.P. (\"VVC IV\") to its partners."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"These securities are held of record by VVC IV. Versant Ventures IV, LLC (\"VV IV\") is the sole general partner of VVC IV and may be deemed to have voting and dispositive power over the securities held by VVC IV and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV IV and may be deemed to indirectly beneficially own the securities through his interest in VV IV. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any."}],"balance_after":720481,"source":{"system":"sec-edgar","filing":"0000899243-21-007816","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000089924321007816/doc4.xml","form_type":"4"}},{"id":2839495,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":126307,"kind":"person","name":"Bolzon Bradley J PhD","position":1,"cik":"0001354345","reported_name":"Bolzon Bradley J PhD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2021-02-23T21:40:01.000Z","date":"2021-02-19","kind":"sale","acquired":false,"shares":3463,"price":151.8198,"value":525751.9674,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These securities are held of record by Versant Venture Management LLC (\"VVM LLC\"), a portion of which are held for the benefit of the Reporting Person, pursuant to an agreement between VVM LLC and the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $151.61 to $151.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (7) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by VVM LLC. The Reporting Person is a managing member of VVM LLC and the Reporting Person may be deemed to indirectly beneficially own the securities through his interest in VVM LLC. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any."}],"balance_after":168831,"source":{"system":"sec-edgar","filing":"0000899243-21-007816","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000089924321007816/doc4.xml","form_type":"4"}},{"id":2839494,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":126307,"kind":"person","name":"Bolzon Bradley J PhD","position":1,"cik":"0001354345","reported_name":"Bolzon Bradley J PhD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2021-02-23T21:40:01.000Z","date":"2021-02-19","kind":"sale","acquired":false,"shares":27932,"price":150.9903,"value":4217461.0596,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These securities are held of record by Versant Venture Management LLC (\"VVM LLC\"), a portion of which are held for the benefit of the Reporting Person, pursuant to an agreement between VVM LLC and the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $150.61 to $151.54, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (6) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by VVM LLC. The Reporting Person is a managing member of VVM LLC and the Reporting Person may be deemed to indirectly beneficially own the securities through his interest in VVM LLC. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any."}],"balance_after":172294,"source":{"system":"sec-edgar","filing":"0000899243-21-007816","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000089924321007816/doc4.xml","form_type":"4"}}],"next_cursor":"2021-02-23T21:40:01.000000Z,2839494"}